trực tiếp đá gà hôm nay

ChemicalBook >> CAS DataBase List >>Ketorolac tromethamine

Ketorolac tromethamine

Chemical Name:
Ketorolac tromethamine
syntex;Ketorolac (Toradol);Ketorolac Thromethamine;KETOROLAC TROMETHAMINE SALT;Godek;TORADOL;Ketanov;Ketorol;Tarazyn;Acular ls
Molecular Formula:
Molecular Weight:
MDL Number:
MOL File:
MSDS File:
Last updated:2025-03-16 07:03:48

Ketorolac tromethamine Properties

Melting point 160-161 C
storage temp. 2-8°C
solubility H2O: 15 mg/mL stable at least one month at −20 °C., soluble
form crystalline
color White to Light yellow
λmax 322nm(MeOH)(lit.)
Merck 14,5306
Stability Hygroscopic
CAS DataBase Reference 74103-07-4(CAS DataBase Reference)
NCI Drug Dictionary


Risk and Safety Statements

Symbol(GHS)  trực tiếp đá gà hôm nayLiên kết đăng nhập
Signal word  Danger
Hazard statements  H301-H315-H319-H335
Precautionary statements  P301+P310+P330-P302+P352-P305+P351+P338
Hazard Codes  T
Risk Statements  25-36/37/38-23/24/25
Safety Statements  26-45-36/37/39
RIDADR  UN 2811 6.1/PG 3
WGK Germany  3
RTECS  UY7759900
HazardClass  6.1(a)
PackingGroup  II
HS Code  2933995500
NFPA 704
2 0

Ketorolac tromethamine price More Price(43)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich K1136 Ketorolac tris salt ≥99%, crystalline 74103-07-4 1g $109.8 2025-03-01 Buy
Sigma-Aldrich 1356665 Ketorolac Tromethamine United States Pharmacopeia (USP) Reference Standard 74103-07-4 200mg $436 2025-03-01 Buy
TCI Chemical K0053 Ketorolac Tromethamine >98.0%(HPLC)(T) 74103-07-4 1g $71 2025-03-01 Buy
TCI Chemical K0053 Ketorolac Tromethamine >98.0%(HPLC)(T) 74103-07-4 5g $261 2025-03-01 Buy
Cayman Chemical 70690 Ketorolac (tromethamine salt) ≥99% 74103-07-4 1g $45 2025-03-01 Buy
Product number Packaging Price Buy
K1136 1g $109.8 Buy
1356665 200mg $436 Buy
K0053 1g $71 Buy
K0053 5g $261 Buy
70690 1g $45 Buy

Ketorolac tromethamine Chemical Properties,Uses,Production


Ketorolac tromethamine is a nonsteroidal antiinflammatory agent that exhibits analgesic and antipyretic activity. The compound is effective in the management of moderate to severe postoperative pain. It is, however, the first of this type of agent to be administered parenterally as an analgesic and is specifically indicated for intramuscular injection. Ketorolac represents a useful alternative to the narcotic analgesics due to its lack of abuse potential.


Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) and a non-selective COX inhibitor (IC50 = 20 nM for both COX-1 and COX-2). It prevents increases in paw swelling, increases paw withdrawal latency in a hot-plate test, and decreases prostaglandin E2 (PGE2) levels in paw tissue in a mouse model of carrageenan-induced inflammation when administered at a dose of 30 mg/kg. Ketorolac is a racemic mixture containing the active (S)-ketorolac and inactive (R)-ketorolac enantiomers. Formulations containing ketorolac have been used to manage postoperative pain and as ophthalmic solutions to treat ocular pain and inflammation.

Chemical Properties

A carboxylic acid derivative nonsteroidal antiinflammatory agent, ketorolac tromethamine occurs as an off-white crystalline powder with a pKa of 3.54 (in water). More than 500 mg are soluble in one mL of water at room temperature. The commercially available injection is a clear, slightly yellow solution with a pH of 6.9 – 7.9. Sodium chloride is added to make the solution isotonic. Ketorolac tromethamine may also be known as RS-37619-00- 31-3; many trade names are available.

Chemical Properties

Off-White to Pale Yellow Solid


Syntex (USA)


Ketorolac is used primarily for its analgesic effects for short-term treatment of mild to moderate pain in dogs and rodents. The duration of analgesic effect in dogs is about 8 – 12 hours, but because of the availability of approved, safer NSAIDs for dogs, its use is questionable.


Analgesic;Cyclooxygenase Inhibitor


Cyclo-oxygenase inhibitor; analgesic; anti-inflammatory.


Ketorolac tromethamine is a pyrrolol-pyrrole nonsteroidal anti- inflammatory agent that inhibits prostaglandin formation. Prostaglandins mediate inflammation within the eye by disrupting the blood-aqueous barrier, inducing vasodilation and increasing intraocular pressure. Prostaglandins may also cause iris sphincter constriction (miosis) independent of cholinergic mechanisms. Ketorolac tromethamine is marketed for use before cataract extraction in human patients (to prevent miosis during surgery) and for control of post surgical inflammation, especially following cataract surgery. It is also approved for management of conjunctivitis associated with seasonal allergy in people. In veterinary medicine, ketorolac tromethamine is primarily used to control surgical or nonsurgical uveitis particularly in cases with concurrent corneal bacterial infection or ulceration when topical corticosteroids are contraindicated. It is also used in diabetic patients, especially smaller patients, adversely affected by systemic uptake of topically applied corticosteroids. Nonsteroidal agents like ketorolac tromethamine can be combined with topical steroids in patients with severe uveal inflammation.


ChEBI: An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.

Manufacturing Process

Preparation of 2-bromo-4-chloro-N-methyl-N-phenylbutanamide
4-Chlorobutanoyl chloride (62 g, 440 mmol) and phosphorus tribromide (3 g) were added to a distillation flask, and heated to 90°C. Bromine (77.5 g, 485 mmol) was added over eight hours, with the solution being allowed to decolorize between additions. After the addition was complete, and the solution decolorized, a vacuum was slowly applied, and the acid gases and phosphorus tribromide scrubbed. Unreacted starting material was distilled at 98-100°C/22 mm Hg, and the temperature slowly increased to 105°C, where a mixture of 2-bromo-4-chlorobutanoyl chloride and 2-bromo-4- chlorobutanoyl bromide began to distill. Pure 2-bromo-4-chlorobutanoyl bromide distilled at approximately 108°C. The combined yield of 2-bromo-4- chlorobutanoyl chloride and 2-bromo-4-chlorobutanoyl bromide was 100.5 g, with a bromide/chloride ratio of approximately 6:1. The mixture of 2-bromo- 4-chlorobutanoyl bromide and chloride is directly usable in the preparation of the butanamide, if desired, or may be separated and either component used.
2-Bromo-4-chlorobutanoyl bromide (300 mmol) was added to a solution of Nmethylaniline (320 mmol) and triethylamine (330 mmol) in toluene (340 mL). The reaction was exothermic, and the mixture was cooled to maintain the temperature at about 40°C. After the addition was complete, the resulting mixture was stirred for 30 minutes, 150 mL water was added, and the mixture was stirred further. The aqueous and organic phases were separated, and the organic phase was washed with 5% hydrochloric acid and with water. The toluene was evaporated completely under vacuum to yield 86.3 g 2-bromo-4- chloro-N-methyl-N-phenylbutanamide (98% yield, approximately 95-96% pure).
A solution of methylmagnesium chloride in butyl diglyme (4.0 L, 2.8 M, 11.2 mol, 2.8 equivalents with respect to 2-bromo-4-chloro-N-methyl-Nphenylbutanamide) was added to a 12 L 4-necked round bottom flask fitted with a mechanical stirrer and two 1 L addition funnels, under a nitrogen atmosphere. 2-Bromo-4-chloro-N-methyl-N-phenyl-butanamide (3.98 mol) was added to the first addition flask, and pyrrole (3.04 equivalents with respect to 2-bromo-4-chloro-N-methyl-N-phenyl-butanamide) was added to the second. The pyrrole was slowly added to the methylmagnesium chloride/butyl diglyme solution at 45-50°C over 3 hours. The resulting viscous mixture was cooled to 25°C and stirred for 30 min. 2-Bromo-4-chloro-Nmethyl-N-phenylbutanamide was added to the resulting mixture over a period of 2 hours at 25-30°C, and the resulting solution was stirred for another 3 hours.
The dark colored reaction mixture was transferred into 5.76 mol 2 N hydrochloric acid with rapid stirring for 1 hour. The aqueous phase was removed, and 0.8 L 15 weight % ammonium chloride in water was added to the organic phase. The resulting mixture was stirred at 35-40°C for 10 min, the aqueous phase then removed, and hexanes (2.4 L) added. The resulting suspension was cooled to -20°C and maintained at that temperature for a few minutes. The precipitate was filtered in a 300 mL sintered glass funnel and washed with hexanes (1 L). Drying of the solid under vacuum at 25-30°C yielded 4-chloro-N-methyl-N-phenyl-2-(2-pyrrolyl)butanamide (81% yield).
A solution of 4-chloro-N-methyl-N-phenyl-2-(2-pyrrolyl)butanamide in toluene was added dropwise at 85°C over 40 min to 1 hour to a stirred suspension of ALIQUAT 336 (phase transfer catalyst, 2 mol % with respect to pyrrolylbutanamide) and granular sodium hydroxide (3 equivalents) in toluene (50 mL). After the addition was complete, the suspension was stirred under a nitrogen atmosphere at a temperature of 85°C for 30 min, then cooled to 35°C. Cooled water (200 mL) was rapidly added to the mixture and stirred for 15 min at 25°C. The solution was rinsed with water and the layers were separated. The organic layer was washed with water, then distilled under atmospheric pressure to recover the toluene and water. The resultant solution was cooled to 50°C and allowed to crystallize after the addition of hexane and a seed crystal. The suspension was cooled to 5°C and stirred for 15 minutes. The resultant precipitate was filtered, washed with 100 mL of hexane, and dried under vacuum at 25°C to yield approximately 38 g (63%) N-methyl-Nphenyl-2,3-dihydro-1H-pyrrolizine-1-carboxamide. This solid was recrystallized from toluene to yield colorless crystals of N-methyl-N-phenyl-2,3-dihydro-1Hpyrrolizine-1-carboxamide, melting point 112-112.5°C.
Benzoyl chloride (4.3 mol) was added dropwise to a rapidly stirring mixture of piperidine (4.3 mol), sodium hydroxide (4.7 mol), toluene (1 L), and water (1.7 L) over a period of 70 min. After the addition was complete, the mixture was stirred at 25°C for one hour. The organic and aqueous phases were separated, and the organic phase was washed with 2 N hydrochloric acid, concentrated by rotary evaporation, and distilled under vacuum to yield benzoylpiperidine as a colorless liquid which crystallized on standing (95% yield, boiling point 169-171°C).
N-Methyl-N-phenyl-2,3-dihydro-1H-pyrrolizine-1-carboxamide (480 mmol) and toluene (100 mL) were added to a mixture of benzoylpiperidine (1.05 eq.) and phosphorus oxychloride (0.96 eq.), which had been stirred at 25°C for 1 hour. An additional 100 mL toluene was added. The suspension was heated to at 40-45°C for 4 hours. The resulting syrup was transferred into a rapidly stirring solution of sodium hydroxide (4.5 mol), piperidine (1.0 mL), and water (650 mL) at 25-35°C and the mixture was stirred for 1 hour. A mixture of toluene (100 mL), water (50 mL), and sodium hydroxide (12 g, 300 mmol) was added to the reaction flask, and the reaction mixture was stirred at 25°C for 1 hour. The suspension was then heated to 75°C and the layers were separated. The organic layer was cooled to 60°C and hexane (100 mL) was slowly added, and the solution slowly stirred and cooled to -15°C. The precipitate was filtered, washed with toluene/hexane (2:1) and then with hexane, and dried under vacuum at 25°C to yield 5-benzoyl-N-methyl-N-phenyl-2,3-dihydro-1Hpyrrolizine-1-carboxamide (83.5% yield).
Preparation of ketorolac tromethamine.
A mixture of 34.4 g (100 mmol) 5-benzoyl-N-methyl-N-phenyl-2,3-dihydro- 1H-pyrrolizine-1-carboxamide, 25 g sodium hydroxide in 25 mL water, and 80 mL methanol was refluxed for 5 hours. The mixture was cooled to room temperature, stirred under nitrogen for sixteen hours, and then diluted with 80 mL of water. The mixture was extracted with toluene, and the aqueous and organic phases were separated. The aqueous phase was acidified with 6 N hydrochloric acid. The resulting precipitate was extracted with dichloromethane. The combined extract was treated with activated clay decolorizing agent (4.5 g) for 30 minutes, filtered, and concentrated byatmospheric distillation. Hexane was added and the mixture allowed to cool to 0-5°C. The product, 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid (ketorolac) was collected by filtration, washed with 100 mL of hexane/dichloromethane (7:3), and dried at 60°C under vacuum, to yield ketorolac (83.4% yield), melting point 152-162°C. Ketorolac (25 g) and 11.9 g tromethamine were dissolved in 175 mL methanol. The solution was filtered and the filter washed with 40 mL methanol. The resulting solution was concentrated by vacuum distillation. Ethylacetate was added to precipitate the ketorolac tromethamine; and the solution was cooled to room temperature for two hours, cooled further to 0°C, and filtered. The precipitate was washed with ethyl acetate/methanol (4:1) and dried under vacuum at a temperature of 65°C, to yield ketorolac tromethamine (95% yield).

brand name

Acular (Allergan); Toradol (Roche);Toradol IM.

Therapeutic Function

Analgesic, Antiinflammatory

General Description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Ketorolac Tromethamine belongs to the class of non-steroidal anti-inflammatory drugs, and its mode of action involves the inhibition of the bodily synthesis of prostagladins. It exhibits anti-inflammatory, antipyretic and analgesic effects.

Biochem/physiol Actions

Ketorolac is a non-steroidal agent that possesses moderate anti-inflammatory activity and is also a potent analgesic. It shows superior analgesic efficacy to that of the opioid analgesics like morphine in patients with moderate to severe postsurgical pain. It inhibits prostaglandin synthesis and platelet aggregation induced by arachidonic acid and collagen. It is a dual COX-1/COX-2 inhibitor.


Like other NSAIDs, ketorolac exhibits analgesic, antiinflammatory, and antipyretic activity probably through its inhibition of cyclooxygenase with resultant impediment of prostaglandin synthesis. Ketorolac may exhibit a more potent analgesic effect than some other NSAIDs. It inhibits both COX-1 and COX-2 receptors.


After oral administration, ketorolac is rapidly absorbed; in dogs peak levels occur in about 50 minutes and oral bioavailability is about 50 – 75%.
Ketorolac is distributed marginally through the body. It does not appear to cross the blood-brain barrier and is highly bound to plasma proteins (99%). The volume of distribution in dogs is reported to be about 0.33 – 0.42 L/kg (similar in humans). The drug does cross the placenta.
Ketorolac is primarily metabolized via glucuronidation and hydroxylation. Both unchanged drug and metabolites are excreted mainly in the urine. Patients with diminished renal function will have longer elimination times than normal. In normal dogs, the elimination half-life is between 4 – 8 hours.

Side effects

The manufacturer indicates that ketorolac tromethamine does not enhance the spread of preexisting corneal fungal, viral or bacterial infections in animal models. Ketorolac tromethamine does not in and of itself induce postoperative pressure elevation other then that which frequently follows cataract extraction in people and animals.

Safety Profile

Ketorolac does cross the placenta. In humans, the FDA categorizes this drug as category C for use during the first two trimesters of pregnancy (Animal studies have shown an adverse effect on the fetus, but there are no adequate studies in humans; or there are no animal reproduction studies and no adequate studies in humans.) In humans, all NSAIDs are assigned to category D for use during pregnancy during the third trimester or near delivery (There is evidence of human fetal risk, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.) Most NSAIDs are excreted in milk. Ketorolac was detected in human breast milk at a maximum milk:plasma ratio of 0.037. It is unlikely to pose great risk to nursing offspring.

Veterinary Drugs and Treatments

Ketorolac is used primarily for its analgesic effects for short-term treatment of mild to moderate pain in dogs and rodents. The duration of analgesic effect in dogs is about 8 – 12 hours, but because of the availability of approved, safer NSAIDs for dogs, its use is questionable.


Limited information is available. The oral LD50 is 200 mg/kg in mice. GI effects, including GI ulceration are likely in overdoses in small animals. Metabolic acidosis was reported in one human patient. Consider GI emptying in large overdoses; patients should be monitored for GI bleeding. Treat ulcers with sucralfate; consider giving misoprostol early.


Ketorolac is relatively contraindicated in patients with a history of, or preexisting, hematologic, renal or hepatic disease. It is contraindicated in patients with active GI ulcers or with a history of hypersensitivity to the drug. It should be used cautiously in patients with a history of GI ulcers, or heart failure (may cause fluid retention), and in geriatric patients. Animals suffering from inflammation secondary to concomitant infection, should receive appropriate antimicrobial therapy. Because ketorolac has a tendency to cause gastric erosion and ulcers in dogs, long-term use (>3 days) is not recommended in this species.
Global( 440)Suppliers
Supplier Tel Email Country ProdList Advantage
airuikechemical co., ltd.
+undefined86-15315557071 China 971 58
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806 China 29797 60
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 China 21698 55
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714 China 9354 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070 CHINA 3012 60
career henan chemical co
+86-0371-86658258 China 29914 58
Jinan Shengqi pharmaceutical Co,Ltd
86+18663751872 CHINA 491 58
Xiamen AmoyChem Co., Ltd
+86-592-6051114 +8618959220845 China 6387 58
Hubei xin bonus chemical co. LTD
86-13657291602 CHINA 22968 58
Chongqing Chemdad Co., Ltd
+86-023-61398051 +8613650506873 China 39916 58

View Lastest Price from Ketorolac tromethamine manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
trực tiếp đá gà hôm nayLiên kết đăng nhập 2025-03-16 Ketorolac tromethamine
US $0.00-0.00 / g 1g 99.9% 20 tons airuikechemical co., ltd.
trực tiếp đá gà hôm nayLiên kết đăng nhập 2024-08-16 Ketorolac tromethamine
US $0.00-0.00 / kg 1kg 99% 100tons Hebei Yanxi Chemical Co., Ltd.
trực tiếp đá gà hôm nayLiên kết đăng nhập 2024-03-24 ketorolac tromethamine
US $0.00 / g 1g 99.9% 200kgs Hebei Bonster Technology Co.,Limited

Ketorolac tromethamine Spectrum

KETOROLAC TRIS SALT KETOROLAC TROMETHAMINE (+/-)-5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLIC ACID, TRIS (HYDROXYMETHYL) AMINOMETHANE SALT (+/-)-5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid tris(hydroxymethyl)methylamine salt (+/-)-5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLIC ACID TRIS SALT KETROLAC TROMETHAMINE SALT (±)-Form tromethamine salt KEROROLACTROMETHAMINE KETOROLACTROMETHAMINE,USP TORADOL TORADOL TRIS SALT 3-dihydro-5-benzoyl-(+-)-compd.with2-1h-pyrrolizine-1-carboxylicaci amino-2-(hydroxymethyl)-1,3-propanediol(1:1) 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) Ketorolac Tromethamine (200 mg)G1E3311.000mg/mg(dr) Toradol, (±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid tris salt Acular ls Acular pf Acular preservative free Godek Tromethamine ketorolac Ketorolac tris salt,(±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid tris salt, Toradol Ketorolac Tromethamine (200 mg) rac Ketorolac TroMethaMine Salt Ketanov Ketorol Tarazyn TroMetaMol Ketorolac KETOROLAC TROMETHAMINE REFERENCE STANDARD 2-amino-2-(hydroxymethyl)propane-1,3-diol 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate 2-Amino-2-(hydroxymethyl)propane-1,3-diol (1RS)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate Toradol,Ketorolac Tromethamine 2-hydroxyethyl-bis(hydroxymethyl)ammonium Ketorolac tromethamine salt (RS37619 tromethamine salt) KetorolacTromethamine> Ketorolac Trometamol/ Ketorolac Tromethamine Ketorolac tromethamine (RS37619 tromethamine) Ketorolac Tromethamine (1356665) Angioamin KETOROLAC TROMETHAMINE SALT syntex Ketorolac (Toradol) Ketorolac Thromethamine KETOROLAC TROMETHAMINE (Inj. Gr.) methyl (1RS)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate ethyl (1RS)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate (±)-5-BENZOYL-2,3-DIHYDRO-1HPYRROLIZINE-1-CARBOXYLIC ACID,2-AMINO- 2-HYDROXYMETHYL)-1,3-PROPANEDIOL Ketorolac Impurity 9 Tromethamine Ketorolac Tromithamine Ketorolac tromethamine impurity-2 Ketorolac tramine 74103-07-4 74103-07- 74103-70-9 C15H13NO3.C4H11NO3 C15H13N1O3 C15H12NO3C4H12NO3 Non-steroidal anti-inflammatory agent and cyclooxygenase (COX) inhibitor that is relatively selective for COX-1.
trò chơi cờ bạc game điện tử máy đánh bạc máy đánh bạc hoàng gia Tải game ăn tiền thật